101
Participants
Start Date
November 30, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Pazopanib
Tablet 800mg qd til progression
Everolimus
tablet 10 mg qd til progression
Pazopanib
tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Everolimus
tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Everolimus
Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
Pazopanib
Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
St. Franciscus Gasthuis, Rotterdam
Medisch Centrum Alkmaar, Alkmaar
Acedemisch Medisch Centrum Amsterdam, Amsterdam
NKI-AVL, Amsterdam
Amphia ziekenhuis Breda, Breda
Maxima Medisch Centrum, Eindhoven
UMC Groningen, Groningen
Atrium Medisch Centrum Heerlen, Heerlen
Medische Centrum Leeuwarden, Leeuwarden
Acedemisch ziekenhuis Maastricht, Maastricht
St. Antonius ziekenhuis, Nieuwegein
Erasmus Medisch Centrum, Rotterdam
Orbis Medisch Centrum, Sittard-Geleen
Haga Ziekenhuis, The Hague
St. Elisabeth ziekenhuis, Tilburg
Isala klinieken, Zwolle
UMC Utrecht, Utrecht
Netherlands Working Group on Immunotherapy of Oncology
OTHER